title: PAX8: a sensitive and specific marker to identify cancer cells of ovarian origin for patients prior to neoadjuvant chemotherapy.
abstract: BACKGROUND
  Neoadjuvant chemotherapy followed by cytoreduction surgery has been used where an accurate cytologic or pathologic diagnosis is usually required before the initiation of neoadjuvant chemotherapy. However, it is difficult to make definitive diagnosis of presence of cancer cells, particularly gynecologic versus non-gynecologic origin, from those ascites specimens due to the absence of specific biomarkers of gynecologic cancers. In the present study, we evaluated if, in addition to the routine morphologic diagnosis, the biomarker PAX8 could be useful in recognition of ovarian epithelial cancer cells prior to the neoadjuvant chemotherapy.
  
  
  METHODS
  Two hundred and two cytology specimens including 120 pretreatment ovarian cancer samples, 60 benign controls, and 22 malignant non-gynecologic cases were studied. All cytology slides were morphologically reviewed in a blinded fashion without knowing corresponding pathology diagnosis, if present. A total of 168 cytology specimens with a cell block were stained with PAX8 and Calretinin. These included patients with potential for ovarian cancer neoadjuvant chemotherapy (n=96), metastatic cancers (n=22), and benign controls (n=50).
  
  
  RESULTS
  Among the 96 ascitic samples prior to neoadjuvant chemotherapy, 76 (79%) showing morphologic features consistent with cancers of ovarian primary were all PAX+/Calretinin-. The remaining 20 (21%) cases were positive for adenocarcinoma, but morphologically unable to be further classified. Among the 22 metastatic cancers into the pelvis, one case with PAX8+/Calretinin- represented a renal cell carcinoma and the remaining 21 PAX8-/Calretinin- metastatic cancers were either breast metastasis (n=4) and the metastasis from gastrointestinal tract (n=17). Among the 50 benign control pelvic washing cases, 5 PAX8+/Calretinin-cases represented endosalpingiosis (n=4) and endometriosis (n=1), 25 PAX8-/Calretinin+cases showed reactive mesothelial cells, and the remaining 20 specimens with PAX8-/Calretinin- phenotype typically contained inflammatory or blood cells without noticeable diagnostic epithelia.
  
  
  CONCLUSIONS
  PAX8 identifies all Müllerian derived benign or malignant epithelia. When combining with Calretinin, PAX8 is a sensitive marker to diagnose the carcinomas of ovarian origin, which will be ideal to be used for those patients with a possible advanced ovarian cancer prior to receiving neoadjuvant chemotherapy.
authors: Department of Obstetrics and Gynecology, Henan Province People’s Hospital, Zhengzhou, Henan 450003, China.
authors: Yue
authors: Y
authors: Wang
authors: Yiying
authors: Y
authors: Wang
authors: Jie
authors: J
authors: Li
authors: Zeng
authors: Z
authors: Yuan
authors: Bingbing
authors: B
authors: Yuan
authors: Tingguo
authors: T
authors: Zhang
authors: Janiel M
authors: JM
authors: Cragun
authors: Beihua
authors: B
authors: Kong
authors: Wenxin
authors: W
authors: Zheng
mesh_terms: D001202:Ascitic Fluid / Q000378:metabolism / Q000473:pathology; D014408:Biomarkers, Tumor / Q000378:metabolism*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D020360:Neoadjuvant Therapy; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D000072636:PAX8 Transcription Factor; D051761:Paired Box Transcription Factors / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; D000072636:PAX8 Transcription Factor; C083325:PAX8 protein, human; D051761:Paired Box Transcription Factors
references: Cancer Cytopathol. 2010 Oct 25;118(5):298-302
references: 20572292
references: Mod Pathol. 2000 Sep;13(9):962-72
references: 11007036
references: N Engl J Med. 2010 Sep 2;363(10):943-53
references: 20818904
references: Gynecol Oncol. 2012 Oct;127(1):198-201
references: 22705448
references: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references: 21296855
references: Am J Surg Pathol. 2010 Mar;34(3):433-43
references: 20154587
references: Indian J Cancer. 2006 Jul-Sep;43(3):117-21
references: 17065769
references: Semin Diagn Pathol. 2005 Feb;22(1):3-32
references: 16512597
references: Gynecol Oncol. 2003 Sep;90(3):644-50
references: 13678739
references: PLoS Med. 2008 Dec 2;5(12):e232
references: 19053170
references: Am J Surg Pathol. 2010 May;34(5):627-35
references: 20414098
references: Am J Surg Pathol. 2011 Jun;35(6):816-26
references: 21552115
references: Arch Pathol Lab Med. 2006 Jun;130(6):823-7
references: 16740034
references: Acta Cytol. 1986 May-Jun;30(3):271-6
references: 3012920
references: Diagn Cytopathol. 1992;8(6):632-40; discussion 640-2
references: 1468343
references: Am J Surg Pathol. 2008 Oct;32(10):1566-71
references: 18724243
references: Gynecol Oncol. 2007 Feb;104(2):331-7
references: 17064757
references: Mod Pathol. 2011 Nov;24(11):1488-99
references: 21701538
references: Hum Pathol. 2011 Jul;42(7):918-31
references: 21683865
references: Am J Obstet Gynecol. 1996 Oct;175(4 Pt 2):1110-3
references: 8885795
references: Diagn Cytopathol. 2012 Aug;40(8):667-72
references: 22807381
references: Diagn Cytopathol. 2011 Aug;39(8):567-74
references: 20607683
references: N Engl J Med. 1993 Nov 18;329(21):1550-9
references: 8155119
references: Appl Immunohistochem Mol Morphol. 2011 Jul;19(4):293-9
references: 21285870
references: Mod Pathol. 2009 Sep;22(9):1218-27
references: 19525927